Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2021 American Headache Society (AHS) Annual Meeting, Showcasing Teva’s Longstanding Heritage in the Management of Migraine
11 presentations examine clinical and real-world AJOVY data in the reduction of migraine days
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),today announced that 11 presentations examining clinical and real-world data for AJOVY® (fremanezumab-vfrm) injection will be presented at the 2021 American Headache Society (AHS) Annual Meeting, taking place virtually June 3-6.
“Our goal is to continue supporting the migraine community through our rigorous and innovative scientific research programs so we can ultimately uncover the full potential of AJOVY for patients,” said Denisa Hurtukova, MD, VP, Head of North America Medical Affairs. “The data being presented at this year’s AHS meeting underscore the impact AJOVY can have on the healthcare community as seen in clinical analyses and real-world experiences.”
Data being presented include results from clinical and real-world analyses and post-hoc Phase 3 data examining the long-term response of AJOVY over the course of 15 months, an analysis of the real-world impact of treatment among patients with comorbid depression, anxiety or hypertension, as well as a Phase 3b analysis examining the consistency in migraine days over the course of a dosing regimen for patients with inadequate responses to 2-4 prior treatments.
This year’s annual AHS meeting is fully virtual. Data presentations can be accessed by registering for the meeting.
The full set of Teva-sponsored AJOVY data to be presented includes:
- Clinically Meaningful Responses to Fremanezumab Treatment in Episodic and Chronic Migraine Over Up to 15 Months
- Real-World Impact of AJOVY Use on Clinical Outcomes Among Migraine Patients With Comorbid Depression, Anxiety or Hypertension
- No Evidence of Wearing Off Effect for Fremanezumab Treatment in Chronic and Episodic Migraine Patients With Inadequate Response to 2-4 Prior Classes of Migraine Preventive Medications
- Sustained, Clinically Meaningful Responses to Fremanezumab Treatment in Migraine Patients With Inadequate Response to 2-4 Prior Classes of Migraine Preventive Medications
- Real-world Reductions in Migraine and Headache Days After Initiating Fremanezumab for US Patients With Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway
- Primary Headache Disorders and Acute Medications Associated With Patients Diagnosed With Medication Overuse Headache: Analysis of US Claims Data
- Real-world Data on Reductions in Migraine and Headache Days With Fremanezumab Treatment for US Patients With Chronic and Episodic Migraine: Results From a Physician Chart Review Study
- Real-world Data on Quarterly and Monthly Fremanezumab for Reducing Migraine Days and Headache Days in US Adult Patients With Migraine: Results From a Physician Chart Review Study
- Real-world Patient Characteristics, Acute Medication Use, and Treatment Patterns for Patients Initiating Fremanezumab Treatment: A US Retrospective Claims Analysis
- Real-world Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab: A US Retrospective Claims Analysis
- Fremanezumab for Preventive Migraine Treatment in Patients With Major Depressive Disorder: Protocol for the Randomized, Placebo-controlled Phase 4 UNITE Study
About AJOVY® (fremanezumab-vfrm) injection
AJOVY is available as a 225 mg/1.5 mL single dose injection in a prefilled syringe or autoinjector with two dosing options – 225 mg monthly administered as one subcutaneous injection, or 675 mg every three months (quarterly), which is administered as three subcutaneous injections. AJOVY can be administered in office byahealthcare professional or at home by a patient or caregiver. No starting dose is required to begin treatment.
Indications and Usage
AJOVY® is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults.
U.S. Important Safety Information about AJOVY® (fremanezumab-vfrm) injection
Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.
Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.
Adverse Reactions: The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.
Please click here for full U.S. Prescribing Information for AJOVY® (fremanezumab-vfrm) injection.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding AJOVY, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
- the commercial success of AJOVY;
- our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; consolidation of our customer base and commercial alliances among our customers; delays in launches of new generic products; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; our ability to develop and commercialize biopharmaceutical products; competition for our specialty products, including AUSTEDO®, AJOVY and COPAXONE®; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize additional pharmaceutical products; and the effectiveness of our patents and other measures to protect our intellectual property rights;
- our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
- our business and operations in general, including: uncertainty regarding the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general; our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith; effectiveness of our optimization efforts; our ability to attract, hire and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the COVID-19 pandemic; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;
- compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; increased legal and regulatory action in connection with public concern over the abuse of opioid medications and our ability to reach a final resolution of the remaining opioid-related litigation; scrutiny from competition and pricing authorities around the world, including our ability to successfully defend against the U.S. Department of Justice criminal charges of Sherman Act violations; potential liability for patent infringement; product liability claims; failure to comply with complex Medicare and Medicaid reporting and payment obligations; compliance with anti-corruption sanctions and trade control laws; and environmental risks;
- other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities (including as a result of potential tax reform in the United States); and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;
and other factors discussed in this press release and in our Quarterly Report on Form 10-Q for the first quarter of 2021 and in our Annual Report on Form 10-K for the year ended December 31, 2020, including in the sections captioned "Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Kevin C. Mannix (215) 591-8912
Yael Ashman 972 (3) 914-8262
Doris Li (973) 265-3752
972 (54) 888 5898
Source: Teva Pharmaceutical Industries Limited